Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancers with dominant-negative p53 mutations are aggressive and treatment-resistant.
• Restoring wild-type p53 function has shown limited clinical success.
• p53 is a critical tumor suppressor gene involved in cell cycle regulation and apoptosis.

Purpose of the Study:

• To investigate targeting a p53-regulated gene to restore tumor-suppressor characteristics in mutant p53 cancers.
• To evaluate the therapeutic potential of inhibiting stathmin in p53-mutated cancer cells.

Main Methods:

• Utilized small interfering RNA (siRNA) to silence stathmin expression in mutant p53 cell lines.
• Assessed the impact of stathmin knockdown on cell proliferation, viability, clonogenicity, cell-cycle regulation, and apoptosis.
• Compared stathmin expression levels in mutant p53 cells to wild-type p53 cells under DNA-damaging conditions.

Main Results:

• Silencing stathmin in mutant p53 cells reduced its expression to levels seen in wild-type p53 cells.
• Stathmin inhibition decreased proliferation, viability, and clonogenicity of mutant p53 cancer cells.
• Knockdown of stathmin partially restored cell-cycle control and induced apoptosis in these cells.

Conclusions:

• Stathmin is overexpressed in the presence of mutant p53.
• Targeting stathmin represents a novel therapeutic strategy for cancers with aberrant p53 function.
• Inhibiting stathmin may reintroduce tumor-suppressor activities lost due to p53 mutations.